Epidemiology and Clinical Features of Invasive Fungal Infection in a US Health Care Network
- PMID: 30151412
- PMCID: PMC6104777
- DOI: 10.1093/ofid/ofy187
Epidemiology and Clinical Features of Invasive Fungal Infection in a US Health Care Network
Abstract
Background: A better understanding of the epidemiology and clinical features of invasive fungal infection (IFI) is integral to improving outcomes. We describe a novel case-finding methodology, reporting incidence, clinical features, and outcomes of IFI in a large US health care network.
Methods: All available records in the Intermountain Healthcare Enterprise Data Warehouse from 2006 to 2015 were queried for clinical data associated with IFI. The resulting data were overlaid in 124 different combinations to identify high-probability IFI cases. The cohort was manually reviewed, and exclusions were applied. European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group Consensus Group definitions were adapted to categorize IFI in a broad patient population. Linear regression was used to model variation in incidence over time.
Results: A total of 3374 IFI episodes occurred in 3154 patients. The mean incidence was 27.2 cases/100 000 patients per year, and there was a mean annual increase of 0.24 cases/100 000 patients (P = .21). Candidiasis was the most common (55%). Dimorphic fungi, primarily Coccidioides spp., comprised 25.1% of cases, followed by Aspergillus spp. (8.9%). The median age was 55 years, and pediatric cases accounted for 13%; 26.1% of patients were on immunosuppression, 14.9% had autoimmunity or immunodeficiency, 13.3% had active malignancy, and 5.9% were transplant recipients. Lymphopenia preceded IFI in 22.1% of patients. Hospital admission occurred in 76.2%. The median length of stay was 16 days. All-cause mortality was 17.0% at 42 days and 28.8% at 1 year. Forty-two-day mortality was highest in Aspergillus spp. (27.5%), 20.5% for Candida, and lowest for dimorphic fungi (7.5%).
Conclusions: In this population, IFI was not uncommon, affected a broad spectrum of patients, and was associated with high crude mortality.
Keywords: Aspergillus; Candida; epidemiology; invasive fungal infection; mucormycosis.
Figures
Similar articles
-
Management of Invasive Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: The Turin Experience.Front Cell Infect Microbiol. 2022 Jan 7;11:805514. doi: 10.3389/fcimb.2021.805514. eCollection 2021. Front Cell Infect Microbiol. 2022. PMID: 35071052 Free PMC article.
-
Invasive fungal infections in Argentine patients with systemic lupus erythematosus.Lupus. 2013 Aug;22(9):892-8. doi: 10.1177/0961203313496342. Epub 2013 Jul 16. Lupus. 2013. PMID: 23861029
-
Invasive fungal infections in pediatric heart transplant recipients: incidence, risk factors, and outcomes.Pediatr Transplant. 2011 Aug;15(5):465-9. doi: 10.1111/j.1399-3046.2010.01415.x. Epub 2010 Nov 26. Pediatr Transplant. 2011. PMID: 21108712
-
The Changing Epidemiology of Invasive Fungal Infections.Methods Mol Biol. 2017;1508:17-65. doi: 10.1007/978-1-4939-6515-1_2. Methods Mol Biol. 2017. PMID: 27837497 Review.
-
Epidemiology of Invasive Fungal Infections in Solid Organ Transplant Recipients: an Indian Perspective.Curr Fungal Infect Rep. 2022;16(4):179-187. doi: 10.1007/s12281-022-00446-w. Epub 2022 Oct 20. Curr Fungal Infect Rep. 2022. PMID: 36281339 Free PMC article. Review.
Cited by
-
Polymicrobial Pseudomonas Plus Candida Parapsilosis Endocarditis in an Injection Drug User: Considerations for Diagnosis and Management.Cureus. 2021 Feb 23;13(2):e13507. doi: 10.7759/cureus.13507. Cureus. 2021. PMID: 33786216 Free PMC article.
-
Pathogenic Drug Resistant Fungi: A Review of Mitigation Strategies.Int J Mol Sci. 2023 Jan 13;24(2):1584. doi: 10.3390/ijms24021584. Int J Mol Sci. 2023. PMID: 36675092 Free PMC article. Review.
-
Active Surveillance Program to Increase Awareness on Invasive Fungal Diseases: the French RESSIF Network (2012 to 2018).mBio. 2022 Jun 28;13(3):e0092022. doi: 10.1128/mbio.00920-22. Epub 2022 May 2. mBio. 2022. PMID: 35499498 Free PMC article.
-
Immunogenicity and protective efficacy of a pan-fungal vaccine in preclinical models of aspergillosis, candidiasis, and pneumocystosis.PNAS Nexus. 2022 Nov 4;1(5):pgac248. doi: 10.1093/pnasnexus/pgac248. eCollection 2022 Nov. PNAS Nexus. 2022. PMID: 36712332 Free PMC article.
-
Role of Antifungal Combinations in Difficult to Treat Candida Infections.J Fungi (Basel). 2021 Sep 6;7(9):731. doi: 10.3390/jof7090731. J Fungi (Basel). 2021. PMID: 34575770 Free PMC article. Review.
References
-
- Pfaller MA, Diekema DJ. Epidemiology of invasive mycoses in North America. Crit Rev Microbiol 2010; 36:1–53. - PubMed
-
- Hobson RP. The global epidemiology of invasive Candida infections—is the tide turning?J Hosp Infect 2003; 55:159–68; quiz 233. - PubMed
-
- Denning DW. Global action fund for fungal infections Available at: https://www.gaffi.org. Accessed 12 December 2017.
-
- Enoch DA, Yang H, Aliyu SH, Micallef C. The changing epidemiology of invasive fungal infections. Methods Mol Biol 2017; 1508:17–65. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous